CHRS
Coherus Oncology, Inc. Healthcare - Biotechnology Investor Relations →
Coherus Oncology, Inc. (CHRS) closed at $2.14 as of 2026-02-02, trading 43.7% below its 200-week moving average of $3.80. This places CHRS in the extreme value zone. The stock moved further from the line this week, up from -43.9% last week. The 14-week RSI sits at 61, indicating neutral momentum.
Over the past 539 weeks of data, CHRS has crossed below its 200-week moving average 11 times. On average, these episodes lasted 38 weeks. The average one-year return after crossing below was -3.5%, suggesting these dips have not historically been reliable buying opportunities for this stock.
With a market cap of $259 million, CHRS is a small-cap stock. The company generates a free cash flow yield of 11.5%, which is notably high. The stock trades at 2.8x book value.
Share count has increased 50.3% over three years, indicating dilution.
Over the past 10.4 years, a hypothetical investment of $100 in CHRS would have grown to $8, compared to $394 for the S&P 500. CHRS has returned -21.8% annualized vs 14.1% for the index, underperforming the broader market over this period.
Free cash flow has been volatile over the past several years, making the quality of earnings harder to assess.
Growth of $100: CHRS vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After CHRS Crosses Below the Line?
Across 11 historical episodes, buying CHRS when it crossed below its 200-week moving average produced an average return of -14.5% after 12 months (median -12.0%), compared to +15.9% for the S&P 500 over the same periods. 27% of those episodes were profitable after one year. After 24 months, the average return was -40.9% vs +37.9% for the index.
Each line shows $100 invested at the moment CHRS crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Historical Touches
CHRS has crossed below its 200-week MA 11 times with an average 1-year return of +-3.5% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Oct 2015 | Oct 2015 | 1 | 0.4% | +23.6% | -91.3% |
| Dec 2015 | Jul 2016 | 31 | 45.8% | +14.5% | -91.3% |
| Feb 2017 | May 2019 | 118 | 62.4% | -59.4% | -90.8% |
| Jun 2019 | Jun 2019 | 1 | 2.2% | +5.1% | -88.1% |
| Jul 2019 | Jul 2019 | 2 | 7.4% | +4.5% | -87.9% |
| Oct 2019 | Oct 2019 | 1 | 4.3% | +4.2% | -87.3% |
| Dec 2019 | Jan 2020 | 2 | 1.2% | -1.0% | -87.8% |
| Mar 2020 | May 2020 | 11 | 21.8% | +8.7% | -85.7% |
| Jun 2020 | Jun 2020 | 3 | 7.9% | -9.8% | -86.7% |
| Mar 2021 | Sep 2021 | 28 | 17.7% | -25.1% | -86.5% |
| Dec 2021 | Ongoing | 215+ | 91.4% | Ongoing | -86.6% |
| Average | 38 | — | +-3.5% | — |
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of Friday close, 2026-02-02